Selection of breast cancer patients for an aromatase inhibitor after radiation and tamoxifen

被引：0
|
作者：
Freedman, GM [1 ]
Anderson, P [1 ]
Li, T [1 ]
Ross, E [1 ]
Swaby, R [1 ]
Goldstein, L [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2005年 / 63卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2005.07.413
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2019
引用
收藏
页码：S242 / S242
页数：1
相关论文
共 50 条
  • [31] Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
    Goebel, Andy
    Kuhlmann, Jan D.
    Link, Theresa
    Wimberger, Pauline
    Link-Rachner, Cornelia
    Thiele, Stefanie
    Dell'Endice, Stefania
    Furesi, Giulia
    Breining, Dorit
    Rauner, Martina
    Hofbauer, Lorenz C.
    Rachner, Tilman D.
    JOURNAL OF BONE ONCOLOGY, 2019, 16
  • [32] The need for DXA assessment of breast cancer patients following 5 years tamoxifen prior to starting an aromatase inhibitor.
    Whannel, K. J.
    McLellan, A.
    Wilson, C. R.
    Doughty, J. C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S187 - S187
  • [33] Activity of exemestane, an irreversible, oral, aromatase inhibitor in metastatic postmenopausal breast cancer patients (MBC) failing tamoxifen (TAM)
    Kvinnsland, S
    Anker, G
    Dirix, LY
    Bonneterre, J
    Prové, AM
    Wiking, N
    De Belder, K
    Mariani, O
    Di Salle, E
    Massimini, G
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S91 - S91
  • [34] Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer
    Dowsett, M
    Pfister, C
    Johnston, SRD
    Miles, DW
    Houston, SJ
    Verbeek, JA
    Gundacker, H
    Sioufi, A
    Smith, IE
    CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2338 - 2343
  • [35] Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors
    Chlebowski, Rowan T.
    Schottinger, Joanne E.
    Shi, Jiaxiao
    Chung, Joanie
    Haque, Reina
    CANCER, 2015, 121 (13) : 2147 - 2155
  • [36] The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance
    Wong, Cynthie
    Chen, Shiuan
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2012, 131 (3-5): : 83 - 92
  • [37] Fulvestrant in advanced breast cancer following following failure of tamoxifen and a third generation aromatase inhibitor
    Wang, J.
    Jain, S.
    Heller, W.
    Mackie, D.
    Watson, V.
    Dweck, M.
    Coombes, R. C.
    Palmieri, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
    S Weeraman
    C Hunsley
    M Wall
    R Kirby
    Breast Cancer Research, 12
  • [39] Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
    Dackus, Gwen M. H. E.
    Jozwiak, Katarzyna
    Sonke, Gabe S.
    van der Wall, Elsken
    van Diest, Paul J.
    Siesling, Sabine
    Hauptmann, Michael
    Linn, Sabine C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (11): : 1506 - 1514
  • [40] A nationwide data on the cardiovascular protective effect of tamoxifen and aromatase inhibitor in postmenopausal women with breast cancer
    Moon, H-G
    Choi, S. H.
    Park, Y.
    Jung, J. G.
    Ju, Y. W.
    Kim, K. E.
    Kim, Y.
    Lee, E.
    Lee, H-B
    Han, W.
    Noh, D-Y
    Yoon, H-J
    CANCER RESEARCH, 2019, 79 (04)
12345